中文
| Catalogue |
|
|
| Recommend Products |
SOTIO Biotech B.V.
Netherlands, Manufacturer, Hits: 442, Updated:11/30/2022
Strawinskylaan 933 1077XX Amsterdam Netherlands |
Company Profile
-
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. The robust SOTIO clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, SOT101, currently being tested in phase II clinical trials. SOT102, a next generation Claudin18.2-targeted antibody-drug conjugate (ADC) has recently entered the clinical phase. BOXR1030, a GPC3-targeted CAR-T based on proprietary technology designed to improve on the efficacy of CAR-T therapies in the tumor microenvironment, will enter the clinical phase in coming months. SOTIO is a member of the PPF Group.
SOTIO is a registered trademark of SOTIO a.s. in selected countries.